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Abstract
Background: South Africa, with its scientific capacity, good infrastructure and high HIV incidence rates, is ideally 
positioned to conduct large-scale HIV prevention trials. The HIV Prevention Research Unit of the South African Medical 
Research Council conducted four phase III and one phase IIb trials of women-initiated HIV prevention options in 
KwaZulu-Natal between 2003 and 2009. A total of 7046 women participated, with HIV prevalence between 25% and 
45% and HIV incidence ranging from 4.5-9.1% per year. Unfortunately none of the interventions tested had any impact 
on reducing the risk of HIV acquisition; however, extremely valuable experience was gained, lessons learned and 
capacity built, while the communities gained associated benefits.
Experience: Our experience in conducting these trials ranged from setting up community partnerships to developing 
clinical research sites and dissemination of trial results. Community engagement included setting up community-
based research sites with approval from both political and traditional leaders, and developing community advisory 
groups to assist with the research process. Community-wide education on HIV/sexually transmitted infection 
prevention, treatment and care was provided to over 90 000 individuals. Myths and misconceptions were addressed 
through methods such as anonymous suggestion boxes in clinic waiting areas and intensive education and 
counselling. Attempts were made to involve male partners to foster support and facilitate recruitment of women. Peer 
educator programmes were initiated to provide ongoing education and also to facilitate recruitment of women to the 
trials. Recruitment strategies such as door-to-door recruitment and community group meetings were initiated. Over 
90% of women enrolled were retained.
Community benefits from the trial included education on HIV prevention, treatment and care and provision of
ancillary care (such as Pap smears, reproductive health care and referral for chronic illnesses). Social benefits included
training of home-based caregivers and sustainable ongoing HIV prevention education through peer educator
programmes.
Challenges: Several challenges were encountered, including manipulation by participants of their eligibility criteria in 
order to enroll in the trial. Women attempted to co-enroll in multiple trials to benefit from financial reimbursements 
and individualised care. The trials became ethically challenging when participants refused to take up referrals for care 
due to stigma, denial of their HIV status and inadequate health infrastructure. Lack of disclosure of HIV status to 
partners and family members was particularly challenging. Some of the ethical dilemmas put to the test our 
responsibility as researchers and our obligation to provide health care to research participants.
Conclusion: Conducting these five trials in a period of six years provided us with invaluable insights into trial 
implementation, community participation, recruitment and retention, provision of care and dissemination of trial 
results. The critical mass of scientists trained as clinical trialists will continue to address the relentless HIV epidemic in 
our setting and ensure our commitment to finding a biomedical HIV prevention option for women in the future.Ramjee et al. AIDS Research and Therapy 2010, 7:10
http://www.aidsrestherapy.com/content/7/1/10
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Introduction
In 2007, Africa accounted for 67% of all people living with
HIV worldwide, with 38% of all new infections occurring
in the southern African region. The predominant route of
HIV transmission in this region is reported to be hetero-
sexual sex [1].
South Africa has the highest adult HIV prevalence
worldwide - 17% in 2008 [2] - and an incidence rate of
1.4% per year (2005 figure) [3]. Some 33% of South Afri-
can women aged between 25 and 29 years are infected
with HIV, while KwaZulu-Natal is the province with the
highest HIV prevalence among persons aged 15-49 years
(26%) [2] and among pregnant women (39%) [4]. The
high HIV prevalence and incidence rates coupled with
good infrastructure make South Africa a location of
choice in which to conduct HIV prevention intervention
trials.
To date, several trials of HIV prevention technologies
have been undertaken in the country, including those of
male circumcision for HIV prevention [5], vaccines [6],
microbicides [7-9], prevention of mother-to-child trans-
mission [10,11], the vaginal diaphragm [12], and the Step-
ping Stone behavioural intervention trial [13], among
others.
The HIV Prevention Research Unit (HPRU) of the
South African Medical Research Council (MRC) has had
the privilege of working with multiple sponsors to con-
duct four phase III and one phase IIb trials of HIV pre-
vention technologies among women between 2003 and
2009 (Table 1).
Methods for Improving Reproductive Health in Africa
(MIRA) was a phase III trial assessing effectiveness of the
latex vaginal diaphragm in prevention of HIV at three
sites in southern Africa (two in South Africa and one in
Zimbabwe) between 2003 and 2006 [12]. Final results
suggested that the diaphragm had no effect on male to
female transmission of HIV infection - hazard ratio (HR):
1.05 (95% confidence interval (CI) 0.84-1.32, P = 0.65)
[12].
Between 2004 and 2007 the phase III trial testing Car-
raguard™, a lead microbicide product of the Population
Council (New York), was conducted at three sites in
South Africa: Isipingo in Durban, Soshanguve in Pretoria
and Gugulethu in Cape Town. The results suggested that
Carraguard™ had no effect on prevention of male to
female transmission of HIV - HR: 0.87 (95% CI 0.69-1.09,
P = 0.302) [8].
The phase III trial testing the effectiveness of cellulose
sulphate (CS) in prevention of HIV among women at high
risk was conducted at several sites in Africa (South
Africa, Uganda and Benin) and a site in India between
2006 and 2007. The trial was stopped prematurely due to
safety concerns during the first Data and Safety Monitor-
ing Committee (DSMC) review in early 2007. Final
results suggested that CS was not suitable for HIV pre-
vention, with no statistically significant effect on safety -
HR: 1.61 (95% CI 0.86-3.01, P = 0.13) [9].
Early in 2009 we heard of the positive but not signifi-
cant effect of 0.5% PRO 2000 in the prevention of HIV
transmission from males to females - HR: 0.71 (95% CI
0.46-1.11, P = 0.1331). The HPTN 035 study, sponsored
by the Division of AIDS (National Institutes of Health),
took place between 2005 and 2008 at two sites in South
A f r i c a  ( D u r b a n  a n d  r u r a l  H l a b i s a )  a s  w e l l  a s  s i t e s  i n
Malawi, the United States of America, Zambia and Zim-
babwe. The phase IIb clinical trial tested the effectiveness
of two candidate microbicides: PRO 2000 (0.5%) and
BufferGel against a placebo and a "no gel" arm [7].
The results of the multi-centre Microbicides Develop-
ment Programme's (MDP) 301 trial [14] were announced
in December 2009. The study tested 0.5% and 2% PRO
2000 against placebo. Unfortunately, PRO 2000, although
safe, was found to have no effect on acquisition of HIV in
this very large trial - HR: 1.05 (95% CI 0.82-1.34, P = 0.712).
The HPRU enrolled a total of 7046 women into these
trials (Table 1), and due to the high HIV prevalence
almost twice that number were screened prior to enrol-
ment. There were a total of 561 HIV seroconversions
among these women.
We report here our experiences in conducting these
community-based HIV prevention trials in KwaZulu-
Natal, South Africa, with a focus on strategies developed
to ensure good data quality, completion of the trial within
an ethical framework, and partnerships developed with
participants, the broader community and other health
care providers. Experiences with these trials have
afforded us the opportunity to evolve methods for trial
implementation which are subject- and location-specific,
but which could also be adapted for use in implementing
clinical trials elsewhere.
All of the trials were approved by local, national and
international ethical and regulatory bodies.
Community Engagement and Partnerships
Setting up community-based research sites
The HPRU set up clinical research sites (CRS) in several
communities in the greater Durban area and one site in a
rural area; we aimed to conduct only one HIV prevention
trial in any given area. Consultation and information ses-
sions were held with community stakeholders and politi-
cal and traditional leaders as part of the community-entry
process, prior to development of the CRS. The commu-
nity leaders in turn discussed the proposal with the
respective community committees before approval was
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granted. Well before initiation or implementation of the
study, community meetings were held to discuss aims,
objectives and potential outcomes, and to provide the
community with background education on HIV/AIDS
prevention, treatment and care, study designs, ethics and
regulatory processes. Community approval was sought in
parallel with trial regulatory approval processes.
Community profile and situational analysis of health 
services
Researchers' understanding of the community was
enhanced by conducting a situational analysis of the demo-
graphics of the community members and the available
health and education resources. The ethical obligation of
clinical trialists to trial participants extends to ensuring
that participants are able to access care for conditions
which are beyond the purview or mandate of a research
site. Thus the situational analysis included development of
a referral log which documented the health and psychoso-
cial care facilities available in the area surrounding the
study sites. This included public and private care facilities,
where researchers engaged facility managers to discuss the
study and the potential need to refer participants for repro-
ductive and other care. We were able to use this informa-
tion to educate the community about the type of care that
was available in their area, and to assist participants in
accessing alternative facilities, should they be concerned
about confidentiality issues arising from attending a facil-
ity in their own community.
Education
Ongoing community education was provided at all levels,
including traditional leaders, non-governmental organisa-
tions (NGOs), community-based organisations (CBOs),
health care providers, women's groups, women and men.
We received requests from community members to
provide education sessions on topics such as the diagno-
sis, treatment and management of tuberculosis (TB), high
blood pressure and diabetes, as well as HIV/AIDS and
other sexually transmitted infections (STIs). These edu-
cation sessions were conducted at locations chosen by the
community and were facilitated by the research clini-
cians, nurses, community liaison officers (CLOs) and out-
reach workers in the local language or English as
required.
Community Working Groups or Community Advisory 
Boards
Key stakeholders were identified to become part of Com-
munity Working Groups (CWGs) or Community Advi-
sory Boards (CABs). Members of the CWGs were either
v o l u n t e e r s  o r  s e l e c t e d  b y  t h e  c o m m u n i t y ,  a n d  w e r e
expected to represent the voice and interests of the com-
munity throughout the research process. CWG member-
ship consisted of men and women between the ages of 30
and 60 years. Initially, CWG membership was dominated
by men who held senior positions in the community - this
has changed over time as more and more women became
involved and empowered; most CWGs are now chaired
by a woman. Women members have included teachers,
managers of health care facilities, representatives from
social development organizations, NGOs and CBOs.
Male members have included political, traditional and
religious leaders, as well as school principals. In total
there were 20 members with equal gender distribution in
Table 1: HIV prevalence and incidence of women participating in trials in KwaZulu-Natal, and overall trial outcome.
Trial
(total enrolment)
Years Location of HPRU sites
(no. enrolled)
HIV prevalence (%) HIV incidence
(/100 woman years)
Overall outcome of 
trial: HR (95% CI)
MIRA
(5045)
2003-2006 Durban
(1515)
39 6.8 1.05
(0.84-1.32) P = 0.65
Carraguard
(6202)
2004-2007 Durban
(1485)
43 6C 0.87
(0.69-1.09) P = 0.302
Cellulose sulphate
(1428)
2006-2007 Durban
(606)
51 5.29 1.61
(0.86-3.01) P = 0.13
HPTN 035
(3101)
2005-2008 Durban (702)
Hlabisa (346)
21.6
28.2
4.6
9.1
0.71
(0.46-1.11) P = 0.1331
MDP 301
(9385)
2005-2009 Durban
(2392)
36 6.1 1.05
(0.82-1.34) P = 0.712
HR = Hazard ratioRamjee et al. AIDS Research and Therapy 2010, 7:10
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each CWG. The education level of members varied from
completion of high school to tertiary education.
In order to facilitate effective participation by CWG
members, training was provided on the principles of eth-
ics, human subject protection, informed consent material
and process, and the study protocol. The CLOs employed
by the HPRU organised regular monthly CWG meetings.
CWG membership was voluntary but members were
reimbursed for transport costs. A budget was allocated
for CWG members to attend conferences, workshops and
meetings both nationally and internationally , as part of
the partnership with and capacity development of com-
m u n i t y  m e m be r s.  W e  f o u n d  t h a t  t h i s  l ev e l  o f  ca pa ci t y
development was an incentive that assisted in retention
of CWG members, who also provided feedback to the
community on the events.
Ongoing communication with trial site community
In addition to attending occasional CWG meetings, the
Principal Investigator also provided feedback on the
study progress at least twice per year, while key staff met
with the community on an ongoing basis. Researchers
and the CWGs were able to discuss challenges and con-
cerns related to the HIV prevention research. Initially,
community members (especially in the rural district of
Hlabisa) expected researchers to provide infrastructure
(roads, sanitation) and employment, and to redress pov-
erty in the area. The role and contribution of researchers
was clarified, emphasising the aim of the research proto-
col, and the importance of HIV prevention education and
research to find safe, effective biomedical technologies to
prevent HIV infection. Once this was clarified, no further
requests were made.
Investigators held ongoing workshops, training sessions
and meetings with CWG members and stakeholders
throughout the duration of each of the trials (approxi-
mately 2-3 years). Clinical site staff also participated in
community events such as Women's Day, World AIDS
Day, and HIV awareness days.
Myths and misconceptions
Since we set up CRS in 'research naïve' communities, there
were many recurrent myths and misconceptions surround-
ing clinical trials, such as: "researchers collect blood to
sell", "researchers infect women with HIV", "women are
being used as guinea-pigs", "researchers pay the women to
use the trial products", "[the researchers] put people and
their families in danger using the GPS [Global Positioning
System] machines", "government condoms have HIV", "the
gel tightens the vagina", "trial staff encourage promiscuity
among women" and "[colposcopic] images are placed on
the Internet". Some of these rumours were published in
local and community newspapers.
The most common myths and misconceptions were
those involving transmission of HIV through research,
misunderstandings concerning regulatory approval of clin-
ical trials, and the selling of blood. Sporadic issues of this
nature were encountered at all trial sites. We addressed
these through outreach and education sessions at various
levels. Participants received group education from CLOs,
counsellors and nurses in clinic waiting rooms. Study staff
were collectively trained on clear communication strate-
gies. We also communicated with CWGs regarding myths
and misconceptions as a means of conveying correct mes-
sages to a broader community. We attempted to provide
additional HIV/AIDS education to the public during
recruitment drives. Re-iteration of messages at various
points assisted us in addressing these issues.
Community participation in trial results messaging and 
dissemination
The ongoing relationships with community stakeholders
and CWGs were extremely useful in formulation of a
suitable language lexicon, messaging, and dissemination
of trial results. Several months prior to the release of
results, we initiated intensive education and information-
sharing sessions to inform the community of trial com-
pletion and the possible outcome scenarios. The HPRU
developed this dissemination plan following the reactions
to closure of the CS trial [15]. Preparing the community
well in advance and providing them with the possible trial
outcome scenarios assisted us in discussing the final
results with minimum challenges.
Involvement of male partners
Although we were conducting trials of women-initiated
HIV prevention options, we soon learned from the
women that covert use was not culturally acceptable,
especially in stable relationships. A strategy was used to
engage men and educate them about clinical trials, HIV,
STIs, safe sex and condom use. Several social events
(such as soccer matches) were arranged at trial sites, after
which education sessions were held to inform men of the
research we were conducting. Involving men in the
research process provided an opportunity for researchers
to reduce the community's misconceptions about HIV
prevention research. Male involvement also resulted in an
increase in women volunteering to participate in the trial,
increased product adherence, and facilitated communica-
tion in participants' personal relationships on issues spe-
cific to their sexual health. A few male partners also
volunteered to come to site for HIV testing and counsel-
ling.
Couple/partner workshops
We held several successful and interactive couples' work-
shops at the sites for study participants and their part-
ners. Study clinicians, nurses, pharmacists and
counsellors educated the couples on the trial protocol,
HIV, STIs, condom usage, family planning, productRamjee et al. AIDS Research and Therapy 2010, 7:10
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adherence, and communication. The men were also
offered voluntary counselling and testing (VCT) services,
blood pressure/blood sugar testing, and measurement of
body mass index.
Recruitment
As described above, ongoing community education and
outreach as well as networking with community stake-
holders occurred before recruitment of women to the tri-
als - which facilitated the recruitment process. We
developed several recruitment strategies to ensure that
we met our target accrual in the protocol-specified time.
Strategies included having regular meetings with the
community, targeting women's groups, getting approvals
from service providers to recruit from family planning
clinics, recruitment at Grant and Home Affairs offices
(governmental agencies), and door-to-door and street
recruitment.
During the recruitment process, field workers distrib-
uted ethics-approved participant information sheets.
These included details of the study, such as study eligibil-
ity criteria, study procedures and laboratory tests, and
information on the investigational products, such as the
safety profile of the intervention. Study staff contact
details were provided so that potential participants could
access further information. In addition, community flyers
in the local languages containing similar information
were distributed throughout the recruitment areas.
Senior staff contacted the heads of organisations such as
health clinics, women's groups, CBOs and faith-based
organisations to seek permission for field staff to recruit
at these venues. Recruitment drives were also undertaken
a t  l a r g e  c o m m u n i t y  m e e t i n g s  a n d  f o r a  s u c h  a s  W o r l d
AIDS Day, World TB Day, Anti-Tobacco Day, etc.
Peer education programme to assist with community 
education and recruitment
Trial participants who displayed a thorough grasp of trial
procedures and who attended their scheduled trial visits
were invited to join our Peer Educators programme,
which was developed in 2005 with the approval of the
local ethics committee. Their role was to provide educa-
tion on HIV prevention, treatment and support, and to
share their own personal experiences of trial participa-
tion. In addition, they undertook the responsibility of
educating women within their residential area about the
trial in order to facilitate recruitment. A total of 50 Peer
Educators were trained, with the objective that these
women would empower others on HIV prevention at
community level. The Peer Educators not only assisted
with recruitment and retention but also with formulation
of trial results messaging and dissemination.
The informed consent process
Informed consent (IC) is an ongoing process in clinical
trials. In the microbicide trials conducted by the HPRU,
both women and the wider community were provided
with information and education on the study through the
media of community awareness flyers, participant study
information sheets, examples of the IC form, and at fre-
quent question-and-answer sessions (conducted both at
the clinic and at community meetings). As outlined by
Woodsong et al [16], this "expanded model of informed
consent" involves the community at the pre-enrolment
stage, and subsequently the individual participant (at
administration of the IC form), followed by continuous
assessment of individual and community perceptions and
reactions to the ongoing study.
We encouraged women to take an unsigned copy of the
IC form home with them, so that they could discuss their
possible participation in the study with their partners or
families prior to enrolment. Once enrolled, a copy of the
signed IC form was provided to participants for reference
purposes, although they were advised that they could
leave their copy at their clinic if they feared that it might
be discovered by family members or partners to whom
they had not disclosed their participation.
Assessment of understanding of the IC process has
shown that the majority of women understood it. How-
ever, some women reported that they had initially experi-
enced difficulty understanding medical or biological
terms such as "gonorrhoea" or "syphilis", but were
assisted by staff members [17]. There has previously been
some indication that women might be experiencing a
therapeutic misconception in relation to HIV prevention
trials [18,19], and we endeavoured to continuously rein-
force and assess comprehension of the blinded nature and
objectives of the trials, and the role and contribution of
participants.
The process of community engagement, including
community awareness activities, engagement of local
community leaders and appointment of the CWG, con-
tributed to acceptance of the IC process instituted in our
trials. We believe that this engagement has indicated
respect for the local communitarian culture, and blended
the more traditional Western and African concepts of
selfhood to produce a form of IC which respects both the
individual and the community [20]. However, we are
aware that the community may still have concerns in this
area - questions regarding the role of male heads of
households in relation to consent of women family mem-
bers to participate are among the most frequently asked
at community feedback activities. We aim to continue to
engage with the community to enhance the IC process,
while also improving awareness of women's right to
autonomy.
Retention of Trial Participants
Retention of trial participants is crucial to ensuring that
we have adequate statistical power to show an effect of
the intervention. Our sponsors developed databasesRamjee et al. AIDS Research and Therapy 2010, 7:10
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which sent reminders of missed visits to staff members.
This information was communicated to field staff, who
contacted women either telephonically and/or through
home visits. In some trials we introduced an award sys-
tem, which provided a gift equivalent in value to ~$2 for
every six months of visits completed, or an award at the
final visit for completion of the trial. In others we pre-
sented women with certificates of completion at their
final visits. This level of acknowledgement was highly
appreciated by study participants.
Addressing participants' concerns to improve retention
Suggestion boxes were placed at each of the sites to allow
women to voice their concerns anonymously, and sugges-
tions were reviewed weekly by the site CLO. Some con-
cerns raised by participants included long waiting times,
unhappiness with performance of certain clinical proce-
dures, discomfort at being examined by male doctors, etc.
Participants were also encouraged to use a toll-free
HPRU clinic number to reschedule their follow-up visits
and/or report any problems which they may have experi-
enced during participation.
End-of-trial retention strategies
During the final stages of the trial, weekend clinics were
held so that participants who were employed could be
accommodated. Women who had relocated to other
areas were transported to the clinic sites or to one of the
remaining six HPRU trial sites for completion of visits.
To ensure high retention at the end of the trial, we con-
ducted some close-out procedures "off-site" (with the
woman's permission) at the woman's home, her place of
work, or any suitable venue indicated by her [21]. Staff
also travelled to other regions of South Africa to trace
women who were enrolled in the trial. Location of
women's residences was included in a geographic infor-
mation system database (with their permission). This
allowed us to identify women's homes and assisted in
tracking those who had missed visits or were lost to fol-
low-up.
Our strategies were successful in retaining over 90% of
women in all our trials (Table 2).
Counselling
Counselling and testing is a basic component of screen-
ing, enrolment and follow-up for participants in clinical
trials. Counselling, as a dedicated profession, is still a rel-
atively new concept in sub-Saharan Africa. However,
given the socially unstable South African context [22], the
importance of counselling messages is vital. Counselling
issues related to confidentiality, condoms, orphans, fami-
lies, cultural beliefs and knowledge are of critical impor-
tance and need to be addressed. Consequently the role of
counselling is paramount and given great consideration
when conducting research.
In our clinical trial setting, three major types of coun-
selling have been conducted: a) HIV and risk reduction
counselling; b) contraception counselling; and c) study
product adherence counselling. It was very important
that the counsellor's approach towards participants was
non-judgmental and conducted in a client-centred man-
ner, and that the messages and approach evolved in
response to contextual cues derived from confidential
data on individual participants' experiences and circum-
stances. Counsellors constructed individual risk reduc-
tion plans through which each participant's progress was
tracked and her future counselling needs profiled.
HIV and risk reduction counselling
We aimed to use HIV testing as a means to promote
behaviour change, in addition to its use as an eligibility
tool during screening and enrolment. HIV education and
pre-test counselling was achieved by providing informa-
tion on: the difference between HIV and AIDS; modes of
HIV transmission; methods of prevention; suggested fre-
quency of testing in relation to an assessment of behav-
ioural risk; the window period and its impact on test
results; correction of myths and misconceptions; and ver-
ifying readiness for testing.
Similarly, risk reduction counselling was also client-
centred: open-ended questions were asked, and counsel-
lors followed techniques of active listening and probing to
identify risk factors and barriers to risk reduction. HIV
post-test counselling included provision and explanation
of test results, explanations of additional testing which
might be required as per the study protocol, and an
assessment of the participant's understanding of the
results.
Contraceptive counselling
Contraceptive counselling on available interventions was
implemented to assist the participant in choosing a
method that she was most likely to adhere to. Nurses and
counsellors were instructed to ask probing questions at
screening or enrolment concerning the participant's
Table 2: High retention rates were evidenced across the 
trials in KwaZulu-Natal.
Trial Retention
MIRA
(average at two sites)
94%
Carraguard 97%
CS 92%
HPTN 035
(average at two sites)
95%
MDP 301
(average at three sites)
96%Ramjee et al. AIDS Research and Therapy 2010, 7:10
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pregnancy intentions and willingness to use a hormonal
or barrier contraceptive method. Nurses were capacity
developed and certified as providers of family planning at
trial sites. This ensured availability of service provision at
the trial site, which reduced the need for off-site referral
for contraceptive uptake post-counselling.
Adherence counselling
Study product adherence counselling commenced on the
first day of enrolment into a particular trial. Counsellors
and pharmacists provided standard information on the
method of administration, mechanism of action, level of
effectiveness, and advantages and disadvantages in the
context of daily use of the study product concerned.
Emphasis was placed on the blinded nature of the trial,
and the necessity to practice safe sex with the use of con-
doms.
Follow-up counselling sessions were structured to
assess adherence since the last session, provide appropri-
ate levels of adherence counselling, develop strategies for
the next month, and reinforce key messages. Given that
adherence to product use is a major challenge in biomed-
ical prevention trials, we suggest that it would be useful
to assess the level of likely adherence to product use prior
to enrolment by asking questions about, for example,
adherence to contraceptives or STI medication as a proxy
to assess potential adherence to new interventions.
Community Benefits from Trials
Community benefits from a trial can be quantitatively
determined at the end of the trial. There are several areas
where the research participants (and therefore the com-
munity) benefit by having a trial conducted in their set-
ting.
HIV prevention, treatment and care education
We have provided HIV prevention, treatment and care
education to approximately 90000 individuals across the
seven communities where the CRSs are based. In addi-
tion, ongoing education continues to be provided as we
implement new research studies at these sites. Peer edu-
cation continues to be included in community activities
on HIV/AIDS prevention.
Ancillary care
Table 3 shows the approximate number of tests and pro-
cedures performed during each of the clinical trials
undertaken. In the public sector in South Africa Pap
smears are only offered to women over the age of 35, with
three pap smears offered per woman. We offered approx-
imately 11 000 Pap smears to women aged between 18
and 50 years. Prevalence of abnormal results varied from
10 - 20% across studies [23,24]. Anaemia was routinely
identified in approximately 10% of the study population
at baseline, while chronic active diseases such as hyper-
tension and diabetes mellitus constituted <5% of findings.
All participants were referred to our health care partners
in the communities for care.
In addition, some 136 000 STI tests were conducted
(Table 3), average prevalence of STIs such as Chlamydia
trachomatis, syphilis and Neisseria gonorrhoeae being 9%,
2% and 2% respectively at screening. A small percentage
(c. 5%) of participants' male partners took up the offer of
STI testing at the CRS. All women were provided with
partner contact cards in an attempt to ensure that their
partners also sought treatment for STIs.
HIV prevention trials target young women of reproduc-
tive age due to the high HIV incidence rates in this age
group; unintended pregnancy in trial participants is a
natural consequence. As per protocol, product use has to
be suspended once pregnancy is detected, and this
impacts as a loss of statistical power to determine prod-
uct effectiveness. In order to retain women on product
and avoid pregnancy, HPRU initiated provision of oral
and injectable hormonal contraception at clinic sites. The
Table 3: Approximate number of tests and services provided to communities by HPRU during the trials.
Test N MIRA Carraguard CS HPTN 035 MDP 301
Pap smear 11 624 1515 5609 - 2108 2392
STIs 136 623 44 572 39 723 16 585 9486 26 257
Pregnancy 94 594 14 857 17 133 8049 21 156 33 399
Colposcopy 299 - - - 299 -
Contraception* 2662 81 (5%) 678 (46%) 98 (16%) 872 (83%) 933 (67%)
CD4 count 120 35 - - - 85
Total number of tests/services 245 922 61 060 63 143 24 732 33 921 63 066
* Percentages are of participants in that trial on contraception.Ramjee et al. AIDS Research and Therapy 2010, 7:10
http://www.aidsrestherapy.com/content/7/1/10
Page 8 of 12
options provided were aligned to those available from the
l o c a l  D e p a r t m e n t  o f  H e a l t h ,  t o  e n s u r e  c o n t i n u i t y  o f
access post-trial. Uptake of contraception from HPRU
sites varied widely across the different protocols (see
Table 3).
HPRU staff counselled 2662 women who were not
using any family planning methods at baseline and pro-
vided them with a contraceptive method of their choice.
We found that many women were not aware of the range
of contraceptive options available, and were therefore
reluctant to go to family planning clinics.
Social benefits
At Hlabisa we trained 150 home-based care-givers to
assist communities with HIV-positive members who
were chronically ill, and in Umkomaas we were successful
in motivating for the opening of a municipal VCT centre.
In addition, HPRU sourced funding to capacitate HIV
clinics with counsellors and doctors in order to manage
the burden of HIV in the community. The training pro-
vided to community members in HIV prevention
research enabled them to seek jobs within the health sec-
tor in their community.
Challenges Encountered
We faced a range of challenges in implementing these tri-
als, and describe some of them below.
Recruitment
As the community became more familiar with the study
inclusion and exclusion criteria, non-eligible women
began to manipulate their responses to facilitate enrol-
ment during the screening visits. This included instances
in which false declarations were made regarding use of
contraception, intention to conceive, number of sex acts
per month, previous instances of HIV testing (women
were attending screening to confirm their HIV status),
and dilution and swapping of urine samples collected for
pregnancy testing (pregnant women swapped their sam-
ples with non-pregnant friends').
We believe this desire to participate in clinical trials
was partially attributable to the high reimbursement rate
of R150 for each scheduled clinic visit throughout the
duration of the trial. This value has been predefined by
the drug regulatory body, the Medicines Control Council
(MCC) of South Africa. For women who have no other
means of income, this may be the motivating factor
encouraging enrolment into a study. Other reasons
included a desire for personalised care and to avoid the
long queues in the public sector centres/services. Despite
this, we also believe that many participants were genu-
inely altruistic in their decision to join trials.
Co-enrolment in other prevention trials
Given the high reimbursement rates (R150 per visit)
approved by the MCC of South Africa, it was inevitable
that participants would try to enrol in more than one
trial, especially in a climate of high unemployment and
disempowerment of women in this very patriarchal soci-
ety. A confidential database was developed based on
women's South African identity numbers, with a real-
time check by staff on every woman screened (14 000)
and enrolled in our trials (7046) [25]. Unfortunately,
while we were able to control for co-enrolments at HPRU
clinical trial sites through our internal checking system,
we were not able to control for women enrolled in trials
with other organisations.
In 2008 we identified 192 co-enrolments with another
trial outside the HPRU. When women were questioned
on their reasons for co-enrolling, they cited "financial
incentives", "better care", and "wanting to register in
another trial before ending on the current one". Fortu-
nately, this did not impact on study outcomes. We hope
to alleviate this problem in the future at trial sites in Kwa-
Zulu-Natal by instituting an electronic biometrics/finger-
printing system which will identify in real time any
potential co-enrolments across sites and institutions. We
will also continue to use our current system to monitor
any co-enrolments at HPRU sites in addition to the fin-
gerprint technology.
Contraception use
Challenges to contraception uptake included participant
apathy based on their own perceptions and beliefs, reluc-
tance to take it due to lack of partner/family support, dif-
ficulty in adhering to the contraception schedules, and
reluctance due to perceived side-effects such as weight
gain. Contraception failure often occurred due to partici-
pants defaulting on contraception visits/schedules, and
f r e q u e n t  m e t h o d  c h a n g e s  d u e  t o  s i d e - e f f e c t s  s u c h  a s
intermenstrual bleeding, nausea and weight gain. Some
participants did not return to the clinics if they became
pregnant, even though it was stressed that they could
remain on the trial.
Retention
A particular retention challenge was experienced in the
rural area of Hlabisa where the population was highly
mobile, and participants frequently migrated or relocated
to urban areas in the province in search of employment.
This necessitated follow-up attempts to locate the partic-
ipants in urban areas, which were not always successful.
Despite this, we were able to retain 96% of women in Hla-
bisa.
Continuity of clinical care
Memoranda of Understanding with service providers to 
ensure continuum of care
A significant challenge during clinical trial implementa-
tion has been ensuring continuity of care of trial partici-
pants. During study participation, clinical management is
governed by protocol-specified clinical procedures. AnyRamjee et al. AIDS Research and Therapy 2010, 7:10
http://www.aidsrestherapy.com/content/7/1/10
Page 9 of 12
aberrations from normal have warranted referral to local
Department of Health clinics/hospitals for further clini-
cal management.
The HPRU established Memoranda of Understanding
(MOU) with the Provincial Department of Health and
local/district health care providers under the jurisdiction
of the overarching Provincial Department of Health
MOU. The MOU ensures continuity of care of research
participants for HIV and reproductive health care
encompassing, among others, management of abnormal
cervical cytology, management of intermenstrual bleed-
ing, as well as management of incomplete and therapeutic
abortions. The MOU also delineates referral for manage-
ment and further investigations of variations from nor-
mal values of blood chemistries together with liver/renal
and haematological readings.
Inadequate health infrastructure
We visited our MOU partners on a quarterly basis to
update them on the study. We were repeatedly informed
about the lack of human resources to manage the high
burden of HIV in the hospital and clinic settings. Manag-
ers at the referral system requested assistance with the
employment of counsellors, clinicians, laboratory staff
(especially to perform PCR for infants), and infrastruc-
ture development. We were able to provide some assis-
tance but not all as requested due to a lack of appropriate
mechanisms to ensure that specific health providers
received the relevant funds.
Perhaps the way forward in bridging the divide between
care provided in research settings and referral to Provin-
cial Department of Health clinics is to enhance more
health services buy-in to the research, by encouraging
more active stakeholder involvement and modifying pro-
tocols to provide more local contextual relevance. In
addition, an overlap or merging of research centres and
local health care providers may prove to be a beneficial
symbiotic relationship, ensuring research objectives are
realised with relevance to the local health care context.
This symbiotic relationship will bridge the divide
between research and public health.
Stigma and reluctance to seek care
Stigma and reluctance to seek care remain major prob-
lems at all trial sites. Participants who were HIV-positive
at the outset were reluctant to seek care at their local clin-
ics/hospitals for fear of friends and relatives finding out
their HIV status, or due to denial of their test results.
These fears were not without foundation; we have
received reports from participants that clinic/hospital
staff divulge confidential information to friends and fam-
ily in the community. Furthermore, those that went to
public clinics had to wait in long queues and join a spe-
cific HIV care programme which assessed disclosure,
adherence to treatment and follow-up. Many participants
believed that they were healthy and did not need to join
the programme.
Reluctance to seek care was also associated with non-
HIV clinical abnormalities which required clinical inter-
vention at hospitals. Referral and/or appointments were
made for further investigations and care. However, many
women were not forthcoming with information about
hospital visits, and upon enquiring at the hospital it was
often found that referred participants had not actually
attended.
Care for HIV seroconverters
The HPRU provided care to participants who serocon-
verted while in the study for the duration of the trial. At
the end of the trial, we were able to perform CD4 cell
counts and viral load assays for some participants to
assist with registering in the local HIV care programme
(see Table 3). However, there was still reluctance to seek
care, even though a detailed referral letter was provided.
For example, we invited seroconverters enrolled in one of
our trials to take part in a care programme which pro-
vided additional counselling and CD4 counts; of the 154
seroconverters, we found that 26% had already accessed
public health care, 23% had enrolled in other treatment
trials, 18% did not wish to participate, and 20% were not
contactable [26].
We noted several instances of rapid HIV progression;
the decision was taken to source private care since the
long waiting lists in local clinics might mean these partic-
ipants would only be attended to several months later.
Furthermore, many women were reluctant to disclose
their results to anyone, which meant that providing care
became very difficult. These women relied more heavily
on the trial staff and this raised concerns of dependency,
especially at the conclusion of our trials.
The reason for HIV status non-disclosure was often
found to be non-acceptance of an HIV-positive test
result. Counsellors would engage participants to discuss
their risk factors (e.g. unprotected sex, multiple partners,
having a male partner with known multiple partners) and
encourage the participants to come to the realisation that
their risky behaviour (or that of their partners) had put
them at an increased risk of acquiring HIV.
The counsellors also provided strategies to assist with
disclosure, and encouraged the participants to identify
potential family members or friends to whom they could
disclose, and from whom they would receive emotional
support. Disclosure was encouraged at each counselling
session in the hope that participants would eventually feel
confident enough to disclose their status. Some partici-
pants were financially reliant on their partners and were
afraid that they would be left destitute if their partner
found out that they were HIV-positive. Counsellors dis-Ramjee et al. AIDS Research and Therapy 2010, 7:10
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cussed employment prospects for these women and
encouraged them to develop their own skills/capacity to
allow them to become less financially reliant on their
partners.
Many women did begin to feel more empowered due to
the patience and encouragement of clinic staff and the
education they received about being HIV-positive, the
care and treatment available to them, and information
about where such care could be accessed.
Ethical boundaries of care in clinical research
During the course of these trials, we identified many
cases in which the ethical boundaries regarding our
responsibility to trial participants were unclear.
Referral to ancillary care has been a point of ethical ten-
sion. For example, a woman who had been screened out
of the trial presented to us with a CD4 count of 20 cells
per mm3. She was so ill that we had to transport and
admit her to the local hospital. Some women became sui-
cidal after learning of their HIV serostatus and expressed
a desire to be cared for by the research site rather than
local HIV care centres. We provided care for an HIV-pos-
itive participant who had contracted TB and was later
paralysed. We sourced hospital and later hospice care for
her.
We have also encountered participants who were not
receptive to counselling or advice: a woman who was HIV
positive continuously defaulted on her contraception; she
had an ectopic pregnancy and had to undergo a termina-
tion. The same participant became pregnant again
despite counselling, and had a premature baby which died
soon after delivery. The same woman defaulted from the
HIV treatment programme several times.
Despite efforts made by us to be ethically responsible, we
realised that the current status of the South African health
system caused many participants to rely on us for care,
which tested our ethical boundaries of responsibility.
Capacity Development
The HPRU collaborations and partnerships with major
international organisations facilitated the development of
a critical mass of clinical trialists, many of whom joined
the MRC with a Master of Science degree and no knowl-
edge of clinical trial implementation. Currently these
world-class clinical trialists are Principal Investigators,
sub-investigators, and Investigators of Record in new tri-
als. In addition, research team members who joined the
Unit as research assistants and fieldworkers were devel-
oped into CLOs, project coordinators and project lead-
ers. A total of 300 staff were employed in these trials at
o u r  p e a k ,  m a n y  o f  w h o m  w e r e  a b l e  t o  o b t a i n  h i g h e r
degrees (Honours, Master of Science, Master in Public
Health, and PhD). In addition, they attended interna-
tional and local meetings and presented at scientific con-
ferences.
We have developed a Good Clinical Practice (GCP)
training programme that includes South African GCP
guidelines and is provided by senior staff who are certi-
fied GCP trainers. All drivers are International Air Trans-
port Association certified to transport hazardous
material. In addition, staff have received training through
sponsors on study implementation, quality control and
quality management. The HPRU is recognised for its
excellent data quality and exceptional chart notes in par-
ticipant files. W e were able to deliver good quality data
and a high retention rate for all five of the trials under-
taken between 2003 and 2009.
Dissemination of Results
Dissemination of results was without incident if the
tested intervention was found to have had no significant
negative effect on risk of HIV infection. However, in cases
in which a more complicated research outcome occurred,
negative media reporting was often encountered, which
severely impacted on community trust in the research
organisation. Extensive efforts to remediate the image of
clinical trials had to be undertaken. We have previously
reported on this issue [15]. W e believe that we need to
communicate to the community from the outset what the
possible outcomes of clinical trials may be, and such sce-
narios should be presented prior to commencement of
the trial (Ramjee et al., unpublished).
Conclusion
The HIV prevention field has so far had little success with
biomedical intervention strategies. However, success also
needs to be acknowledged in the changes which trial par-
ticipants initiate in their lives following education and
counselling sessions at CRS. This may spread to the wider
community through their social networks.
Hypotheses generated for investigation in human trials
were based on observations and pre-clinical animal and
laboratory studies. Based on unsuccessful trial outcomes,
it is difficult when implementing new trials to convince
the community that evidence for the new concept also
comes from data generated from animal or laboratory
studies.
Recent failures with interventions such as vaccines [6],
microbicides [8,9,27], HSV2 suppressive therapy [28,29]
and vaginal diaphragms [12] have been extremely difficult
f or  t he  fie l d as a  w hole .  U nf o rt u na t e ly ,  wit h hi gh HIV
incidence rates among young women, decreasing the
effort to find an effective HIV prevention intervention is
not an option. The community and all our stakeholders
need to understand these challenges and support contin-
ued research on HIV prevention.Ramjee et al. AIDS Research and Therapy 2010, 7:10
http://www.aidsrestherapy.com/content/7/1/10
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We urgently need political will and commitment
together with a co-ordinated effort in partnership with
scientists, civil society, activists and other relevant organ-
isations to address the unacceptably high HIV incidence
rate in our setting. The lessons learned here provide
invaluable insights into conducting clinical trials in mid-
dle-income countries such as South Africa. Our experi-
ence and lessons learned will be of importance to others
in similar settings. With a critical mass of scientists devel-
oped as world-class clinical trialists, we hope to build on
the lessons learned as we move forward to test new HIV
prevention interventions for women and men.
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